revenue growth
-6–-4 pct
FY 2027
official guidance
| Revenue | $4.9B |
|---|---|
| Operating income | $46.7M |
| Net income | $545,000 |
| Free cash flow | $94.5M |
| Operating margin | 0.9% |
| Net margin | 0.0% |
| Return on equity | 0.0% |
| Period | TTM 2026-06-30 |
OpenFilings analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
Profitability is protected, but demand stabilization and the brand turnaround remain unproven.
Latest call · Q1 2027Hold: Under Armour lowered FY2027 revenue guidance to a mid-single-digit decline after Q1 revenue fell 3% to $1.1 billion, with North America down 9%, DTC down 6% and e-commerce down 12%; Q2 is expected to decline at a high-single-digit rate. Maintaining adjusted operating income guidance of $140–$160 million and targeting 220–270 bps of gross-margin expansion shows cost control, but the earnings defense relies heavily on SG&A cuts, prior-period tariff refunds and disciplined discounting rather than improving demand. Bouncy Tee and SKU rationalization are credible early positives, but deteriorating traffic, aggressive competitor promotions and unproven conversion of brand moments into footwear and broader sales do not support a clean buy yet.
Q2 guidance calls for high-single-digit revenue decline, adjusted operating income of $10–$20 million and adjusted diluted EPS of negative $0.01 to negative $0.03.
Back-half product launches, DICK'S retail initiatives and full-price selling are expected to improve North American trends, but management explicitly rejected a major revenue hockey stick.
Bouncy Tee sell-through at its full $65 price, upcoming Helix Tee launch at $35 and performance footwear commercialization are key tests of premiumization.
Gross-margin performance will depend on resisting discounting while absorbing tariffs, foreign exchange and approximately $35 million of expected Middle East conflict impacts.
Management is targeting an additional 25% SKU reduction over 18 months and roughly a 40% or greater overall SKU reduction by the end of 2028, aiming to improve style productivity, inventory quality and full-price sell-through.
The turnaround thesis depends on converting athlete wins and technical product credibility into repeatable consumer demand; management acknowledged that strong moments such as Boston Marathon and World Cup wins have not yet translated sufficiently into commercial sales, particularly footwear.
North America and APAC remain structural risk areas: Q1 revenue declined 9% and 7%, respectively, while China also faced stockouts and licensee discounting.
Free cash flow is expected to be positive this year, with $396 million of cash and $200 million drawn on the revolver, reducing near-term balance-sheet risk but not resolving the operating turnaround.
Analyst questioning exposed an unresolved inventory issue: despite a planned 25% SKU reduction, management would not quantify expected liquidation or markdowns and said inventory should generally trend with revenue as new full-price purchases offset discontinued styles.
Traffic in North America and APAC deteriorated materially from late May, and management said North American traffic was not yet stabilized; the forecasted back-half improvement rests on launches and retail execution rather than a demonstrated demand inflection.
Marketing is being reduced to the lower end of the 10%–11% of revenue range even as management argues the brand needs stronger storytelling. The claimed efficiency gains are not quantified, and the risk is underinvestment during a turnaround.
Management acknowledged that competitors are winning and clearing inventory aggressively, especially in Europe and the UK, creating a promotional environment that could undermine Under Armour's full-price strategy.
The $140–$160 million adjusted operating-income outlook is maintained despite lower revenue partly through SG&A reductions, Q1 outperformance and approximately $70 million of IEEPA tariff refunds, making the earnings outlook less indicative of underlying demand health.
revenue growth
-6–-4 pct
FY 2027
official guidance
operating margin
2.2–2.7 pct
FY 2027
official guidance
operating margin
140–160 $million
FY 2027
official guidance
revenue growth
-9–-7 pct
Q2 2027
official guidance
operating margin
10–20 $million
Q2 2027
official guidance
adjusted eps
-0.03–-0.01 $per share
Q2 2027
official guidance
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
UNDER ARMOUR, INC.
UNDER ARMOUR, INC.
UNDER ARMOUR, INC.
UNDER ARMOUR, INC.
UNDER ARMOUR, INC.
UNDER ARMOUR, INC.